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AbstrACt 
Objectives To investigate the trend in the launch price of 
new drugs for five common health conditions.
Design Cross-sectional study using data on new 
drugs launched in the UK between 1981 and 2015 for 
hypertension, asthma, rheumatoid arthritis, schizophrenia 
and colorectal cancer.
Data and sources All drugs marketed in the UK between 
1981 and 2015 (inclusive), and licensed specifically for 
the treatment of one of the five chosen conditions were 
included in the study. Newly launched medicines and 
their launch prices were identified by hand-searching all 
editions of the British National Formulary in addition to 
searching the websites of relevant regulatory agencies 
(European Medicines Agency and Medicines and 
Healthcare products Regulatory Agency). The launch price 
in UK pounds for a 28-day supply of each medicine at 
a typical or usual maintenance dose was adjusted for 
the effects of general inflation using the gross domestic 
product deflator series.
results 104 drugs were included in our study with a 
mean inflation-adjusted 28-day launch price of £288 (SD 
£678). The launch price of new drugs varied significantly 
across the five conditions, with drugs for hypertension 
having the lowest mean price (£27) and drugs for 
colorectal cancer having the highest mean price (£1590) 
(p<0.001). There were large increases in launch prices 
across the study period, but the magnitude and pattern 
was markedly different between therapeutic areas. 
Biological drugs represented 13.5% of all included drugs 
and had a significantly higher launch price than non- 
biological drugs (£1233 vs £141, p<0.001). 22.1% of 
included drugs were first-of-kind and had a significantly 
higher launch price than follow-on drugs (£768 vs £151) 
(p<0.0001).
Conclusion Drugs prices continue to increase across 
different therapeutic areas. This has some association 
with novelty, but, it is not clear if this increase in price is 
associated with medical benefits.
bACkgrOunD
Over last few decades, the expense on health-
care has risen faster than economic growth 
in many developed countries.1 2 Internation-
ally, expense on pharmaceuticals represents a 
significant proportion of the total healthcare 
budget.3 For example, high-income countries 
within the Organisation for Economic Co-op-
eration and Development spend, on average, 
18% of their total healthcare expenditure on 
medicines and this figure can reach up to 
80% in some low- and middle-income coun-
tries.3 In the UK, the expenditure on medi-
cines represented 11.6% of total healthcare 
expenditure in 2008.1 
Worldwide, affordability is a major compo-
nent of ensuring access to essential medicines 
for many conditions.4 5 Affordability reflects 
both price and volume, and many publicly 
funded healthcare providers, including the 
UK National Health Service (NHS), aim to 
provide effective treatment at a price that 
represents value for money.6 Healthcare 
systems in many countries, including in the 
UK, use a variety of cost-saving and cost-con-
taining measures in order to counter financial 
challenges. A government-wide agreement 
with industry to cap increases in overall 
expenditure on branded medicines (the 
Pharmaceutical Price Regulation Scheme) 
and ensuring approval and reimbursement 
strengths and limitations of this study
 ► The timeline of this study enables a very long-term 
view of drug pricing that goes beyond previously 
published work.
 ► This study used the British National Formulary to 
identify new drugs and new licensed indications 
for existing marketed drugs and is therefore likely 
to represent a comprehensive view of drug pricing 
in the UK.
 ► This study is restricted to publicly available pricing 
data in the UK; the actual price paid by healthcare 
providers for drugs may vary from this and the re-
sults may not be applicable to other settings.
 ► This study chose to focus on five health conditions 
in a pragmatic way, and the results may not be gen-
eralisable to drugs licensed for use in other health 
conditions.
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of drugs is dependent on an assessment of clinical and 
cost-effectiveness using Health Technology Assessment 
(HTA), which may include restrictions on patient eligi-
bility.6 An understanding of the drivers of medicine prices 
is therefore important, particularly when countries and 
policy makers are seeking to develop pricing policies that 
improve both the availability and the affordability of such 
medicines.3
The increasing cost of pharmaceuticals used to manage 
a number of common conditions has received increasing 
attention in recent years.4 7 In the USA, retail prescrip-
tion drug spending accelerated in 2014, growing 13.1% 
in 1 year, representing the largest annual increase since 
2003.8 According to a recent report that considered the 
impact of changes in the pharmaceutical industry and its 
impact on healthcare payers in the USA,8 this increase 
was the result of increasing demand and changes in 
patient behaviour, both of which had a significant impact 
on drug expenditures.
However, innovation or novelty is also a factor, as pricing 
of first-of-kind drugs was noted to be one of the most 
important factors driving this trend.8 Studies on rising 
overall pharmaceutical expenditure seen during the 
1990s to mid-2000s in North America and Europe have 
highlighted the role played by both increased utilisation 
and the adoption of newer, more expensive medicines.9 10 
The high cost of newer agents has been identified by some 
commentators as the key component of rising per-pa-
tient pharmaceutical costs for cancer chemotherapy and 
the treatment of diabetes mellitus, glaucoma, psychosis, 
multiple sclerosis and haemophilia.11 12 However, other 
studies suggest increasing utilisation as the major driver 
of rising costs in the treatment of hypertension, hyper-
lipidaemia, depression and rheumatoid arthritis, where 
increasing overall pharmaceutical spending has not 
necessarily been accompanied by increased per-patient 
spending.13–15
Increases in the cost of newer medicines has been 
variously explained as due to increasing regulatory and 
technology assessment requirements, research and devel-
opment costs, attrition rates, production costs, the patent 
system and marketing practice.16–22 To further investi-
gate trends in the price of pharmaceuticals, we sought to 
describe long-term, 35-year trends in the launch price for 
all new medicines marketed in the UK to treat one of five 
common conditions.
MethODs
selection of disease areas and identification of new drugs
All medicines marketed in the UK for the first time 
between 1981 and 2015 (inclusive) for the treatment 
of one the following five conditions were included in 
the study using International Statistical Classification 
of Diseases version 10 (ICD-10)23: (1) asthma (ICD-10 
code J45), (2) colorectal cancer (ICD-10 code C18), (3) 
essential hypertension (ICD-10 code I10), (4) rheuma-
toid arthritis (seropositive rheumatoid arthritis (ICD-10 
codes M05 and M06)) and (5) schizophrenia (ICD-10 
code F20). These diseases were selected by consensus 
of the six members of the National Institute for Health 
Research Horizon Scanning Research and Intelligence 
Centre research group to represent a range of physical 
and mental health disorders for which significant phar-
maceutical innovation over the period of interest was 
known to have occurred.
Our study included medicines specifically licensed for 
the treatment of one of these conditions at the time of 
first UK launch (as described in the Summary of Product 
Characteristics (SmPC) published by the European 
Medicines Agency (EMA)24 and Medicines and Health-
care products Regulatory Agency (MHRA),25 as appro-
priate as well as existing licensed drugs that subsequently 
received marketing authorisation for one of the five study 
conditions, including those that have subsequently been 
withdrawn.
Medicines were identified by hand-searching all 
editions of the British National Formulary (BNF)26 
published between 1981 and 2015. The BNF lists all medi-
cines available for prescription and dispensing within the 
UK irrespective of whether they are available on the NHS; 
the date of first appearance in the BNF (for new medi-
cines) or the date where the indication was amended in 
the BNF (for existing licensed medicines subsequently 
receiving marketing authorisation for one of the speci-
fied conditions) was taken to be the year of launch in the 
UK. Medicines listed in BNF edition 1 were considered 
to be already be available for use in 1981, and therefore 
excluded from the study. This approach to identifying all 
relevant new medicines was supplemented by searches 
of the electronic Medicines Compendium (Datapharm 
Communications),27 commercial pharmaceutical data-
bases (Adis Insight (Springer))]8 and Pharmaprojects 
(Informa Healthcare),29 the websites of relevant regu-
latory agencies (EMA and MHRA),24 25 and searches for 
clinical practice guidelines issued by the National Insti-
tute for Health and Clinical Excellence (NICE)30 and 
relevant specialist clinical societies and associations.
We had no patient or public involvement as part of this 
study.
Price calculation
To allow price comparisons within each disease area, 
the launch price in UK pounds for a 28-day supply of 
each medicine at a typical or usual maintenance dose 
(including cycles or courses where relevant) was calcu-
lated from the unit price provided in the edition of the 
BNF in which the medicine first appeared. Initial loading 
or lower introductory doses were ignored. The published 
SmPC and/or relevant clinical guidelines were consulted 
when no usual dose was listed in the BNF. The dose 
range mid-point was used when no usual dose could be 
established (adjusted to be achievable using available 
dose formulations). In all cases, the price was calculated 
using the least expensive combination of available dose 
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formulations (where relevant, this assumed wastage, a 
body weight of 76.9 kg, and body surface area of 1.7 m2).
The 28-day launch prices for all medicines were 
adjusted for the effects of general inflation using the gross 
domestic product (GDP) deflator series.31 GDP deflators 
serve as a measure of inflation within the economy as a 
whole for a given time period and were used to adjust 
prices to 2015 values, thereby allowing direct compari-
sons between prices at different time points.
We excluded new combinations of existing licensed 
medicines and those not found in the BNF.
Data handling and analysis
Data on drug name, whether it was newly launched or 
an existing licensed and available product, the mech-
anism of action or drug class, whether the drug was a 
biological agent, launch year, launch price for a typical 
28-day supply and 2015-adjusted 28-day launch price 
were extracted and entered onto an Excel spreadsheet. 
Where the mechanism of action or drug class was not 
stated in the BNF, it was obtained from the commercial 
Pharmaprojects database. Statistical analysis was carried 
out using IBM SPSS V.21 for Windows. Trends in adjusted 
28-day launch prices were initially explored using simple 
descriptive statistics and scatter plots. Descriptive analyses 
were presented as means and SD for normally distributed 
continuous variables. Significant differences were deter-
mined using analysis of variance for continuous normally 
distributed data and Χ2 for dichotomous variables.
results
One hundred and four drugs met our inclusion criteria, 
representing approximately 10% of all new drugs 
launched for all conditions over the period of the study.32 
They were launched with an inflation-adjusted 28-day 
price that ranged from £2.20 (methotrexate for rheu-
matoid arthritis, 1992) to £4200.70 (bevacizumab for 
colorectal cancer, 2006) (table 1). Nearly one third of 
the drugs were launched for hypertension (34.6%), while 
just 10.6% were launched for colorectal cancer. There 
were statistically significant differences in the mean infla-
tion-adjusted 28-day launch price by condition, with drugs 
for hypertension having the lowest mean price (£27) and 
drugs for colorectal cancer having the highest mean price 
(£1,590) (p<0.0001).
Drug characteristics
The majority of the drugs included in the study were 
newly launched (92.3%) as opposed to new licensed 
indications for existing marketed drugs (9.6%). The 
mean inflation-adjusted 28-day price for newly launched 
drugs was higher than that for new licensed indications 
for existing marketed drugs. This pattern was observed 
across all three relevant conditions (asthma, rheumatoid 
arthritis and colorectal cancer), but the differences were 
not statistically significant (table 2).
Fourteen (13.5%) of the included drugs were biolog-
ical agents, almost two thirds of which were for rheuma-
toid arthritis, and none of which were for hypertension 
or schizophrenia. Over the three relevant conditions, 
biological drugs had a significantly higher mean infla-
tion-adjusted 28-day launch price than non-biological 
drugs (£1233 vs £141, p<0.001).
Newly launched biologics had nearly twice the mean 
inflation-adjusted 28-day launch price of the two newly 
licensed indications for existing marketed biological 
drugs (£1322 vs £691), however this difference was not 
statistically significant.
Pattern of change in pricing
A large increase in inflation-adjusted 28-day launch 
prices was observed when all drugs included in this study 
were considered together. However, the magnitude and 
pattern of change varied considerably between the five 
therapeutic areas (figure 1).
For hypertension, following the introduction of capto-
pril in 1981, the typical price of newly launched drugs 
generally fell (with some variation) until the early 1990s, 
after which prices appeared to stabilise. For asthma, there 
was a single high-cost outlier (omalizumab, launched 
in 2006), but there was also a sharp increase in launch 
price in 1987 with the launch of nedocromil sodium (a 
cromoglicate), which was nearly three times the infla-
tion-adjusted price of the previously launched drug. 
The overall trend in the price of newly launched drugs 
for schizophrenia was broadly flat. However, there were 
some significant variations across the period of interest. 
Table 1 Number of drugs and their 28-day inflation-adjusted launch price by selected condition launched in the period 1981 
to 2015 (inclusive), includes newly licensed drugs as well as new licensed indications for existing marketed drugs. Prices 
adjusted to 2015 values using the gross domestic product deflator series.
Selected condition n (%) Mean price (SD) Median price (range)
Hypertension 36 (34.6) £27.01 (13.09) £23.48 (7.40–59.10)
Asthma 18 (17.3) £64.73 (175.10) £21.32 (8.60–764.50)
Schizophrenia 15 (14.4) £130.31 (86.56) £131.25 (19.40–331.80)
Rheumatoid arthritis 24 (23.1) £347.16 (414.24) £69.71 (2.20–1052.20)
Colorectal cancer 11 (10.6) £1590.30 (1426.65) £1105.20 (83.04–4200.70)
Total 104 £287.67 (678.34) £37.76 (2.20–4200.70)
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In particular, two drugs launched in 1990 showed a great 
discrepancy in inflation-adjusted 28-day launch price, 
with the price of clozapine (£332.80, the first atypical 
antipsychotic launched) being nearly 10-fold higher 
than that of loxapine (£31.75), which was launched the 
same year. For rheumatoid arthritis, launch prices expe-
rienced a marked upward step in 1999 with the arrival 
of infliximab (tumor necrosis factor [TNF]-α inhibitor), 
the first biological agent licensed for this condition. This 
was followed by a slight decrease in the inflation-adjusted 
Table 2 Mean 28-day inflation-adjusted launch price by selected condition according to biological vs non-biological drug 
type, first-of-kind vs follow-on drug, and new drug vs new indication for existing marketed drug, 1981–2015.
Selected condition
Biological 
drug
Non-biological 
drug First-of-kind Follow-on New drug
New licensed 
indication
Hypertension £31.50 £26.50
P=0.47
Asthma £764.50 £23.60 £283.90 £20.90 £70.40 £19.20
P<0.001 P=0.01 P=0.71
Schizophrenia £331.80 £115.90
P=0.01
Rheumatoid arthritis £813.90 £211.90 £451.80 £227.40 £389.70 £329.90
P=0.001 P=0.31 P=0.79
Colorectal cancer £2225.48 £1227.35 £2368.44 £941.86 £1741.03 £83.04
P=0.28 P=0.10 P=0.29
All conditions £1232.76 £140.65 £768.25 £151.21 £293.19 £221.34
P<0.001 P<0.001 P=0.78
Figure 1 Inflation-adjusted 28-day launch price of newly licensed drugs and new licensed indications for existing marketed 
drugs for one of five selected conditions, 1981 to 2015 (inclusive).
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price the following year when the next drug was launched 
(by 12.5%). Launch prices for drugs licensed to treat 
colorectal cancer rose increasingly rapidly in the two 
decades following the mid-1990s. In particular, the intro-
duction of bevacizumab in 2006, the second biological 
drug for this condition, resulted in a nearly threefold 
increase in the inflation-adjusted 28-day launch price 
compared with drugs launched in the previous few years.
Drug class/mechanism of action
The 104 drugs included in our study represented 34 
different drug classes or mechanisms of action, 17 of 
which were represented only once. There were signifi-
cant variations in the inflation-adjusted 28-day launch 
price for drugs by drug class/mechanism of action; these 
differences were statistically significant across all but one 
of the therapeutic areas (the exception being drugs for 
colorectal cancer) (supplementary appendix 1).
Among the 36 drugs from nine drug classes included 
for hypertension, α1-adrenergic receptor antagonists had 
the highest mean inflation-adjusted 28-day launch price 
(£36.50) followed by angiotensin converting enzyme 
(ACE) inhibitors (£35.00). For asthma, the anti-IgE 
humanised monoclonal antibody, omalizumab, had the 
highest inflation-adjusted launch price by far (£764.45). 
The next most expensive was the single cromoglicate 
(£42.74), followed by leukotriene receptor antagonists 
(£37.58) and selective β2-agonists—long acting (£31.21). 
The lowest mean inflation-adjusted 28-day launch price 
was for selective β2-agonists—short acting (£11.62). For 
rheumatoid arthritis, nearly one third of drugs (29.2%) 
were non-steroidal anti-inflammatory drugs , and there 
was a marked downward trend in their launch prices 
between 1985 and 1996 (mean adjusted 28-day launch 
price for the whole period £40.76). TNF-α inhibitors 
were the second common group of drugs launched for 
rheumatoid arthritis, and these had a mean inflation-ad-
justed launch price of £898.53, though single examples 
of an interleukin (IL)-1 inhibitor, an inhibitor of T-cell 
co-stimulation and IL-6 inhibitors were priced even 
higher. Almost one third of all new drugs launched for 
colorectal cancer were thymidylate synthase inhibitors, 
which had a mean inflation-adjusted 28-day launch price 
£513.78. The launch price for this class of drugs showed 
a dramatic, more than 10-fold increase between 1992 
and 2001, but even so the mean launch price was still 
the lowest of all drug classes/mechanisms of action iden-
tified for this condition. Drugs for schizophrenia were 
grouped into two broad categories, recognising the diffi-
culty of ascribing a specific class or individual mechanism 
of action. Atypical antipsychotics had significantly higher 
inflation-adjusted 28-day launch price (£156.93) than first 
generation antipsychotics (£23.80) (p<0.01).
First-of-kind and follow-on drugs
Less than a quarter of the drugs included in our study 
(22.1%) represented the first of a new class of drugs 
or a new mechanism of action (first-of-kind). However, 
these drugs had a significantly higher inflation-adjusted 
28-day launch price than follow-on drugs (£768 vs £151, 
p<0.0001) (table 2). However, within therapy areas, a 
statistically significant difference between first-of-kind and 
follow-on drugs was only observed for asthma and schizo-
phrenia (both p<0.01). First-of-kind drugs represented 
almost half of all newly launched drugs for colorectal 
cancer, a proportion that was greater than for any other 
indication.
We identified nine examples where the first-of-kind 
and at least one follow-on drug were launched in the 
time period of this study; two each of these drug classes/
mechanisms of action were licensed for colorectal cancer, 
asthma, hypertension and rheumatoid arthritis, and one 
was licensed for schizophrenia. In general, it was apparent 
that inflation-adjusted launch prices generally fell over 
time, particularly as the time from when the first-of-kind 
was launched increased (figure 2). The overall decrease 
in inflation-adjusted 28-day launch price from the first-
of-kind to the final launch of a follow-on varied between 
-£2.00 (selective cyclo-oxygenase-2 inhibitors for rheuma-
toid arthritis) to -£259.99 (TNF-α inhibitors for rheuma-
toid arthritis), and in relative terms varied between −6.6% 
(selective cyclo-oxygenase-2 inhibitors for rheumatoid 
arthritis) to −83.9% (ACE inhibitors for hypertension). 
The exceptions were the two epidermal growth factor 
receptor (EGFR) inhibitors for colorectal cancer, where 
panitumumab was priced over 160% higher than cetux-
imab, the first-of-kind.
DisCussiOn
Main findings
Our findings show that while launch prices of drugs 
have generally increased over the study period, after 
controlling for inflation there were marked differences 
according to therapeutic area, with some showing no real-
term increase. In addition, the launch price of first-of-kind 
drugs is consistently higher than that of other drugs, and 
that biological agents are considerably more expensive at 
launch that other drugs marketed for the same condition.
Pharmaceutical companies argue that the price of 
new drugs is set at a level needed to recoup the vast 
costs incurred in bringing that drug to market, as well as 
fund future research and development.33–35 These costs 
have risen over time for a number of reasons, including 
the increasing complexity and length of clinical trial 
programmes to meet the needs of regulators and HTA 
bodies,36–39 so that, by some estimates, the rate of new 
drug launches per R&D spend has fallen by around a 
half every 9 years since the 1950s.40 However, R&D costs 
per drug candidate are not transparent for commercial 
reasons, and the oft quoted cost of bringing a new drug to 
market may fail to properly account for publicly funded 
basic and translational research.34 In our study, the mean 
inflation-adjusted 28-day launch price for drugs indicated 
for colorectal cancer was almost 59 times greater than 
the price of those for hypertension. We cannot directly 
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account for different drug development costs across 
different disease areas, but this finding may reflect the 
headroom for therapeutic gain in colorectal cancer when 
compared with hypertension. Our data appears to agree 
with the general observation made by commentators that 
managing cancer is expensive and the prices for drugs 
associated with cancer represent a great burden to health-
care systems.36 41 Howard et al36 reported that the average 
adjusted launch price of anticancer drugs increased by 
10% annually between 1995 and 2013, which is consid-
erably less than the increase in inflation-adjusted launch 
price of drugs for colorectal cancer we observed in the 
period 1985 to 2013. Launch prices spiked in 2006 with 
the introduction of the biological drug, bevacizumab, 
which might be expected given the increased develop-
ment and manufacturing costs associated with biological 
agents.34 This pattern of increased drug costs associated 
with the introduction of the first biological drug mirrored 
that seen in rheumatoid arthritis, but unlike rheumatoid 
arthritis, commentators have argued that this pressure on 
prices seen in cancer is not related to the magnitude of 
expected health benefit.36
We also found that first-of-kind drugs were more expen-
sive at launch and that where our data included both 
first-of-kind and follow-on drugs, the price of subsequent 
launches was lower but still rather closely related to that 
of the first launch. This pattern is readily explained 
by the market into which new and follow-on drugs are 
launched, with first-of-kind drugs competing with estab-
lished drugs for the same condition or creating a new 
market if no equivalent treatment exists. The premium 
given to first-of-kind drugs could be justified if payers are 
willing to pay more to receive a substantial therapeutic 
advance compared with existing drugs or other treat-
ment options.33 In our data, this may partly explain the 
very marked differences between areas where there is 
limited scope for new drugs to markedly improve care. 
The idea of ‘rewardable innovation’ suggests that health 
services and patients place value on improvements in a 
wide range of domains, including those related to new 
molecular structures, drug synthesis, pharmacodynamics, 
pharmacokinetics, drug delivery, pharmacogenetics and 
application in clinical practice.42 However, many newly 
launched drugs do not offer any therapeutic advance 
for patients41 and even many first-of-kind drugs do not 
provide any clinically significant innovation.43
strengths and limitations of the study
We believe our study includes all drugs newly launched 
in the UK for the five indicated conditions over a 35-year 
Figure 2 Relative (%) change in inflation-adjusted 28-day launch price of follow-on drugs compared with first-of-kind drugs 
by number of years since launch of first-of-kind. ACE, angiotensin converting enzyme; EGFR, epidermal growth factor receptor; 
TNFa, tumor necrosis factor; VEGF, vascular endothelial growth factor. 
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period. However, we chose the five conditions on a prag-
matic basis, and generalisability from our findings cannot 
be assumed, particularly in drugs for rare or orphan 
conditions, which were not part of our study. In addition, 
the published list price for drugs may not be the actual 
price paid by NHS organisations, particularly for the 
more recently launched drugs, as this fails to account for 
the effects of local price negotiations and the increasing 
use of patient access schemes. These predominate in new 
cancer drugs, and tend to be of an order sufficient to yield 
a cost-utility ratio acceptable to NICE, but their impact 
would tend to blunt the apparent increase in price over 
time for a particular condition, whereas our data still show 
a marked increase in the inflation-adjusted price of new 
drugs for colorectal cancer. Finally, we acknowledge that 
our decision to standardise comparisons on the basis of a 
28-day supply of medicines could be criticised as failing to 
note that treatment for some conditions and with some 
medications could potentially be lifelong, and hence 
generate much higher total costs for payers. Indeed, 
some innovations in cancer could be life-extending, and 
so overall costs could escalate further, although with 
important health gains. However, our principal compari-
sons were within disease areas, and in general, this means 
treatments are given for a similar duration or course.
Conclusions
While prices for new drugs continue to increase overall, 
this masks significant disparities between therapeutic 
areas. It is unclear to what extent these patterns repre-
sent developers passing on real differences in devel-
opment and manufacturing costs or different pricing 
strategies based on an assessment of the current market 
and payers' willingness to pay more for some conditions. 
Increased prices could be justified where new drugs meet 
an unmet clinical need42 43 and could encourage devel-
opers to focus efforts in priority fields, where higher risk 
might reasonably be rewarded by higher returns. Publicly 
funded healthcare systems demand value for money, but 
existing pricing systems lack the transparency to ensure 
access to drugs at reasonable and justified prices.
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